Bridging the Scales via Personalized Cellular Modeling and Deep Phenotyping in Schizophrenia [0.03%]
整合多尺度精神分裂症研究的个性化细胞模型和深度表型构建方法
Florian J Raabe,David Popovic,Clara Vetter et al.
Florian J Raabe et al.
Importance: While growing evidence implicates synaptic dysfunction as a key pathophysiological mechanism in cognitive impairments in schizophrenia (SCZ), it remains unknown how individual alterations in synaptic connectiv...
Evaluation of Large Language Model Chatbot Responses to Psychotic Prompts [0.03%]
评估大型语言模型聊天机器人对精神病提示的回复
Elaine Shen,Fadi Hamati,Meghan Rose Donohue et al.
Elaine Shen et al.
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial [0.03%]
抗药性抑郁患者中艾司西酞普兰(es许可西普兰)对照安慰剂的随机临床试验
Wieslaw J Cubala,Malek Bajbouj,Michael Bauer et al.
Wieslaw J Cubala et al.
Importance: Few pharmacotherapies are approved for treatment-resistant depression, and many patients do not achieve remission following treatment with those therapies. ...
Colm Healy,Kirstie O&#x;Hare,Ulla Lång et al.
Colm Healy et al.
Importance: Methylphenidate is the leading pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in childhood and adolescence. Individuals with ADHD have a higher risk of psychosis, but the long-te...
Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions: A Systematic Review and Meta-Analysis [0.03%]
一项系统评价和meta分析：在相同揭盲条件下，针对抑郁症，迷幻疗法与抗抑郁药的对照研究
Zachary J Williams,Hannah Barnett,Balázs Szigeti
Zachary J Williams
Importance: Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding, which biases results when comparing PAT with blinded interventions. Because PAT is effectively always open label, treatment ...
James I Hudson,Harrison G Pope Jr
James I Hudson
Dost Öngür
Dost Öngür
Roger D Weiss,Edward V Nunes,Scott E Provost
Roger D Weiss
Transdiagnostic Patterns of Grip Strength in Schizophrenia, Current Depression, and Remitted Depression [0.03%]
贯穿于精神分裂症、当前抑郁症和缓解期抑郁的手握力量特征模式
Sofie von Känel,Anastasia Pavlidou,Niluja Nadesalingam et al.
Sofie von Känel et al.
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial [0.03%]
氯胺酮难治性抑郁症患者的疗效和安全性：EPISODE随机临床试验
Lea J Mertens,Michael Koslowski,Felix Betzler et al.
Lea J Mertens et al.
Importance: Psilocybin shows promise in treating depression, although limitations of previous research warrant further research. Objective: ...